Modality
Nanobody
MOA
KRASG12Ci
Target
BCL-2
Pathway
Lipid Met
SCD
Development Pipeline
Preclinical
~Jul 2021
→ ~Oct 2022
Phase 1
Jan 2023
→ Dec 2028
Phase 1Current
NCT03456778
1,800 pts·SCD
2023-01→TBD·Terminated
NCT05370496
855 pts·SCD
2025-11→2028-12·Not yet recruiting
2,655 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-11-087mo awayNDA· SCD
2028-12-232.7y awayInterim· SCD
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1
Termina…
P1
Not yet…
Catalysts
NDA
2026-11-08 · 7mo away
SCD
Interim
2028-12-23 · 2.7y away
SCD
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03456778 | Phase 1 | SCD | Terminated | 1800 | eGFR |
| NCT05370496 | Phase 1 | SCD | Not yet recr... | 855 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-8550 | Roche | Approved | BCL-2 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| ARG-4339 | Argenx | Phase 2 | BCL-2 | |
| GMA-729 | Genmab | Phase 2 | BCL-2 |